GTC Biotherapeutics (fka GTCB)

[jessellivermore]

As noted you are entitled to your opinions.

You think the differences between the glycolisation patterns on Atryn and those of plasma derived AT3 will be materially significant (you are interested as an investor).

You think an important goal for the company is to replace cell culture protein production with GTCB's transgenic platform.

You are unquestionably a bright individual so with your opinions it's difficult for me to understand why you would be interest in GTCB unless it's from a short position.

You go further by opining the market for Atryn will be in the 5-6MM/yr range which is at varience with the company's estimate.

You denegrate the possibility (would this be another "eye roll") that Atryn might be of clinical benefit in DIC. Gosh as a clinical surgeon I find the clinical reports that keep coming pretty compelling ( dumb me I'm only an MIT and Havard Med grad).

As for your prediction the factor VII plan is doomed to failure at the hands of the new improved CHO vats. Me I'm going to stick with LFB on this one. But then again what do they know about the plasma protien market?

Who controls the Spice controls the universe